Skip to content

Study · In vitro (cell-free) · 2013

5 results

The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.

Li J, Cheng Y, Zhang X, Zheng L, Han Z, Li P, Xiao Y, Zhang Q, Wang F

Cancer letters14 May 2013Cited by 32 (Europe PMC)

PMID23684552 (opens in a new tab)DOI10.1016/j.canlet.2013.05.006 (opens in a new tab)PepBankPUB-23684552
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    Thymosin alpha‑1 bound toll-like receptor 2 with a lower affinity than the fusion peptide.

    In plain wordsIn lab tests, thymosin alpha‑1 bound toll-like receptor 2 less tightly than the fusion peptide did.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableBinding affinity of Tα1 to TLR2
    Study

    n: not reported in source

    Surface plasmon resonance binding
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    KD
    35.4 μmol/L
    Tα1 binding to TLR2

    Source sentences

    Summary
    Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5.
    1 context sentence
    Summary · context
    In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    The thymosin alpha‑1-thymopentin fusion peptide alleviated immunosuppression induced by hydrocortisone in vivo.

    In plain wordsIn animals, a fusion peptide made of thymosin alpha‑1 and thymopentin reduced immune suppression caused by hydrocortisone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHydrocortisone-induced immunosuppression
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    It was found that Tα1-TP5 (305 μg/kg) alleviated immunosuppression induced by hydrocortisone (HC).
    1 context sentence
    Summary · context
    In the present study, the immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide (Tα1-TP5) was investigated in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    The fusion peptide combined with cyclophosphamide inhibited tumor growth better than cyclophosphamide alone.

    In plain wordsIn animals, the fusion peptide plus cyclophosphamide slowed tumor growth more than cyclophosphamide alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor growth inhibition with cyclophosphamide
    Study

    n: not reported in source

    Comparator
    Cyclophosphamide alone
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Tα1-TP5 (305 μg/kg) combined with cyclophosphamide (CY) had a better tumor growth inhibitory effect than CY alone.
    1 context sentence
    Summary · context
    In the present study, the immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide (Tα1-TP5) was investigated in vivo.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Activity measurement

    The fusion peptide bound toll-like receptor 2 with a higher affinity than thymosin alpha‑1.

    In plain wordsIn lab tests, the fusion peptide bound toll-like receptor 2 more tightly than thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableBinding affinity of Tα1-TP5 to TLR2
    Study

    n: not reported in source

    Surface plasmon resonance binding
    Comparator
    Tα1
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    KD
    6.84 μmol/L
    Tα1-TP5 binding to TLR2

    Source sentences

    Summary
    Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5.
    1 context sentence
    Summary · context
    In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 05LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Activity measurement

    The affinity of the fusion peptide for toll-like receptor 2 was not significantly different from that of thymopentin.

    In plain wordsIn lab tests, the fusion peptide and thymopentin bound toll-like receptor 2 about equally well.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTLR2 affinity of Tα1-TP5 versus TP5
    Study

    n: not reported in source

    Surface plasmon resonance binding
    Comparator
    Thymopentin (TP5)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5.
    1 context sentence
    Summary · context
    In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.